1-(4-甲基环己基)乙酮 | 1879-06-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(4-甲基环己基)乙酮
• 中文别名: 1-(4-甲基环己基)乙基酮
• 英文名称: 4-acetyl-1-methylcyclohexane
• 英文别名: 1-(4-methyl-cyclohexyl)-ethanone；1-(4-Methyl-cyclohexyl)-aethanon；4-Methyl-hexahydro-acetophenon；1-Methyl-4-acetyl-cyclohexan；4-methylcyclohexyl methyl ketone；1-Acetyl-4-methyl-cyclohexan；Ethanone, 1-(4-methylcyclohexyl)-；1-(4-methylcyclohexyl)ethanone
• CAS: 1879-06-7
• 化学式: C₉H₁₆O
• 分子量: 140.225
• InChiKey: HTAYNGUDHFAFFQ-UHFFFAOYSA-N

物化性质

• 沸点：
  196°C (estimate)
• 密度：
  0.9055

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2914299000

反应信息

• 作为反应物：
  描述：

  1-(4-甲基环己基)乙酮 在 乙醇 、 sodium 作用下， 生成 1-(4-甲基-环己基)-乙醇
  参考文献：
  名称：

  Wallach; Ritter, Justus Liebigs Annalen der Chemie, 1911, vol. 381, p. 92

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(4-甲基-环己基)-乙醇 在 chromium(III) oxide 、 硫酸 作用下， 生成 1-(4-甲基环己基)乙酮
  参考文献：
  名称：

  van Woerden, Recueil des Travaux Chimiques des Pays-Bas, 1926, vol. 45, p. 137

  摘要：

  DOI：

文献信息

• Substituted Imidazopyridines as HDM2 Inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20140179680A1

  公开（公告）日：2014-06-26

  The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

  本发明提供了如本文所述的取代咪唑吡啶或其药用可接受的盐或溶剂。代表性化合物可用作HDM2蛋白的抑制剂。还公开了包括上述化合物的药物组合物以及使用它们治疗癌症的潜在方法。
• [EN] PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES<br/>[FR] PROCÉDÉ DE SYNTHÈSE DE CARBAMATES CYCLIQUES
  申请人：LONZA AG

  公开号：WO2012048884A1

  公开（公告）日：2012-04-19

  The invention is directed to a process for the preparation of a cyclic carbamate starting with a chiral propargylic alcohol and/or a suitable salt thereof, which is reacted with a cyclisation agent selected from phosgene, diphosgene, triphosgene and mixtures thereof, and in that the reaction is carried out in the presence of an aqueous base, and a water-immiscible organic solvent, said organic solvent mainly comprising at least one compound selected from C2-5-alkyl C2-5-carboxylates and mixtures of at least one C2-5-alkyl C2-5-carboxylate with at least one C5-8-alkane. Another aspect of the invention is directed to a process for the synthesis of said cyclic carbamate starting described above, wherein also a process for the preparation of the chiral propargylic alcohol is provided.

  本发明涉及一种以手性炔丙醇和/或适当的盐为起始物，通过选择光气、二光气、三光气及其混合物作为环化剂进行反应，以制备环状碳酸酯的方法，其中反应在水性碱和与水不混溶的有机溶剂的存在下进行，所述有机溶剂主要由至少一种C2-5-烷基C2-5-羧酸酯和至少一种C2-5-烷基C2-5-羧酸酯与至少一种C5-8-烷烃的混合物组成。发明的另一方面涉及上述描述的环状碳酸酯的合成过程，其中还提供了制备手性炔丙醇的方法。
• MODULATORS OF THE RELAXIN RECEPTOR 1
  申请人：The United States of America, as Represented by the Secretary, Dept. of Health & Human Services

  公开号：US20150119426A1

  公开（公告）日：2015-04-30

  Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R 1 , and R 2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.

  本文揭示了人类松弛素受体1的调节剂，例如，公式（I）中的A、R1和R2如本文所定义，这些调节剂在治疗哺乳动物松弛素受体1介导的人类健康方面，例如心血管疾病中是有用的。还公开了一种包含药用适宜载体和本公开的至少一种化合物的组合物，以及一种用于治疗介导人类松弛素受体1的哺乳动物健康方面的干预方法。
• [EN] GOLD (I)-PHOSPHINE 1,2,3-TRIAZOLE DERIVATIVES WITH ANTIOBIOTIC PROPERTIES<br/>[FR] DÉRIVÉS D'OR (I)-PHOSPHINE 1,2,3-TRIAZOLE PRÉSENTANT DES PROPRIÉTÉS ANTIBIOTIQUES
  申请人：UNIV STRASBOURG

  公开号：WO2019243273A1

  公开（公告）日：2019-12-26

  The present invention relates to gold (l)-phosphine 1,2,3-triazole compounds, and their use in a human or animal medicine. The present invention also relates to using such compounds for the prevention and/or treatment of an infection, i.e. inhibitors of growth of Gram-positive and/or Gram-negative bacteria. On another aspect the invention relates to the synthesis of the gold (l)-phosphine compounds of the invention and to their synthesis intermediates. The present invention finds applications in the medical, veterinary and/or chemical fields.

  本发明涉及金(l)-膦1,2,3-三唑化合物及其在人类或动物药物中的应用。本发明还涉及使用这类化合物预防和/或治疗感染，即抑制革兰氏阳性和/或革兰氏阴性细菌的生长。另一方面，本发明涉及合成本发明的金(l)-膦化合物及其合成中间体。本发明在医学、兽医和/或化学领域中找到应用。
• [EN] FUEL COMPOSITIONS COMPRISING ISOPRENE DERIVATIVES<br/>[FR] COMPOSITIONS DE CARBURANT CONTENANT DES DÉRIVÉS D'ISOPRÈNE
  申请人：DANISCO US INC

  公开号：WO2011160081A1

  公开（公告）日：2011-12-22

  The invention provides for methods, compositions and systems using isoprene from a bioisoprene composition derived from renewable carbon for production of a variety of hydrocarbon fuels, fuel additives, and additives for fine chemistry and other uses.

  这项发明提供了利用从可再生碳源衍生的生物异戊二烯组合物中提取异戊二烯的方法、组合物和系统，用于生产各种烃燃料、燃料添加剂以及精细化学和其他用途的添加剂。